NEW YORK, September 29, 2015 /PRNewswire/ --
Equity Research Institute has initiated coverage on the
following equities: Mylan N.V. (NASDAQ: MYL), Zoetis Inc. (NYSE:
ZTS), Ironwood Pharmaceuticals Inc. (NASDAQ: IRWD), Akorn Inc.
(NASDAQ: AKRX), and Supernus Pharmaceuticals Inc. (NASDAQ: SUPN).
Free research report on Mylan can be accessed at
https://www.erionline.net/MYL.pdf On Monday,
September 28, 2015, the NASDAQ Composite ended at 4,543.97,
down 3.04%, the Dow Jones Industrial Average declined 1.92%, to
finish the day at 16,001.89, and the S&P 500 closed at
1,881.77, down 2.57%. The losses were broad based as all the
sectors ended the session in negative. Register for your
complimentary reports at the links given below.
Mylan N.V.'s stock declined 6.31%, to close the day at
$40.86. The stock recorded a trading
volume of 17.42 million shares, much above its three months average
volume of 7.52 million shares. Over the last one month and over the
past three months, Mylan N.V.'s shares have plummeted 20.64% and
39.58%, respectively. Furthermore, the stock has lost 27.51% since
the start of this year. The company's shares are trading 23.59%
below their 50-day moving average. Additionally, Mylan N.V. traded
at a PE ratio of 18.74 and has a Relative Strength Index (RSI) of
21.13. Sign up and read the free notes on MYL at:
https://www.erionline.net/MYL.pdf
On Monday, shares in Zoetis Inc. recorded a trading volume of
8.94 million shares, higher than their three months average volume
of 3.65 million shares. The stock ended the day 6.00% lower at
$39.96. Shares of the company traded
at a PE ratio of 48.14. Zoetis Inc.'s stock has lost 12.87% in the
last one month, 14.96% in the previous three months and 6.63% on
YTD basis. The company is trading below its 50-day and 200-day
moving averages by 13.99% and 13.37%, respectively. Furthermore,
shares of Zoetis Inc. have an RSI of 28.50. The complimentary notes
on ZTS can be downloaded in PDF format at:
https://www.erionline.net/ZTS.pdf
Ironwood Pharmaceuticals Inc.'s stock declined 3.20%, to close
Monday's session at $9.99. The stock
recorded a trading volume of 1.80 million shares, above its three
months average volume of 1.58 million shares. Over the last one
month and the previous three months, Ironwood Pharmaceuticals
Inc.'s shares have lost 9.59% and 13.81%, respectively.
Additionally, the stock has plummeted 34.79% since the start of
this year. The company is trading 9.78% and 26.90% below its 50-day
and 200-day moving averages, respectively. Furthermore, Ironwood
Pharmaceuticals Inc.'s stock has an RSI of 33.30. Register for free
on Equity Research Institute and access the latest research on IRWD
at:
https://www.erionline.net/IRWD.pdf
Akorn Inc.'s stock finished Monday's session 8.64% lower at
$29.29. A total of 2.38 million
shares were traded, which was above its three months average volume
of 1.17 million shares. Over the last one month and the previous
three months, Akorn Inc.'s shares have plummeted 28.93% and 31.15%,
respectively. Additionally, the stock has declined 19.09% since the
beginning of 2015. The company's shares are trading below their
50-day and 200-day moving averages by 29.71% and 33.54%,
respectively. Akorn Inc.'s stock traded at a PE ratio of 91.53 and
has an RSI of 18.56. The complete research on AKRX is available for
free at:
https://www.erionline.net/AKRX.pdf
On Monday, shares in Supernus Pharmaceuticals Inc. ended the
session 12.43% lower at $14.51. The
stock reported a trading volume of 1.36 million shares, above its
three months average volume of 0.90 million shares. Shares of the
company traded at a PE ratio of 21.03. Supernus Pharmaceuticals
Inc.'s shares have declined 17.18% in the last one month and 11.15%
in the previous three months. However, the stock has surged 74.82%
on YTD basis. The company is trading 5.52% above its 200-day moving
average. Moreover, shares of Supernus Pharmaceuticals Inc. have an
RSI of 27.13. Free in-depth research on SUPN is available at:
https://www.erionline.net/SUPN.pdf
--
About Equity Research Institute:
Equity Research Institute ("ERI") produces regular sponsored and
non-sponsored reports, articles, stock market blogs, and popular
investment newsletters covering equities listed on NYSE and NASDAQ
and micro-cap stocks. ERI has two distinct and independent
departments. One department produces non-sponsored analyst
certified content generally in the form of press releases, articles
and reports covering equities listed on NYSE and NASDAQ and the
other produces sponsored content (in most cases not reviewed by a
registered analyst), which typically consists of compensated
investment newsletters, articles and reports covering listed stocks
and micro-caps. Such sponsored content is outside the scope of
procedures detailed below.
ERI has not been compensated; directly or indirectly; for
producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by
a writer (the "Author") and is fact checked and reviewed by a third
party research service company (the "Reviewer"). Rohit Tuli, a CFA® charter holder (the
"Sponsor"), provides necessary guidance in preparing the document
templates. The Reviewer has reviewed and revised the content, as
necessary, based on sound investment judgment and publicly
available information which is believed to be reliable. The
Reviewer and the Sponsor have not performed any independent
investigations or forensic audits to validate the information
herein. Unless otherwise noted, any content outside of this
document has no association with the Author, the Reviewer, or the
Sponsor (collectively referred to as the "Production Team") in any
way. The Production Team is compensated on a fixed monthly basis
and do not hold any positions of interest in any of the securities
mentioned herein.
NO WARRANTY
ERI, the Author, the Reviewer and the Sponsor (collectively
referred to as the "Publishers") are not responsible for any error
which may be occasioned at the time of printing of this document or
any error, mistake or shortcoming. No liability is accepted by the
Publishers whatsoever for any direct, indirect or consequential
loss arising from the use of this document. The Publishers
expressly disclaim any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance
placed on the information in this document. Additionally, the
Publishers do not (1) guarantee the accuracy, timeliness,
completeness or correct sequencing of the information, or (2)
warrant any results from use of the information. The included
information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or
a solicitation of an offer to buy or sell the securities mentioned
or discussed, and is to be used for informational purposes only.
Please read all associated disclosures and disclaimers in full
before investing. Neither ERI nor any party affiliated with us is a
registered investment adviser or broker-dealer with any agency or
in any jurisdiction whatsoever. To download our report(s), read our
disclosures, or for more information, visit
http://www.erionline.net.
RESTRICTIONS
ERI is not available to residents of Belarus, Cuba, Canada,
Iran, North Korea, Sudan, Syria
or Somalia.
CFA® and Chartered Financial Analyst® are registered trademarks
owned by CFA Institute.
SOURCE www.erionline.net